NASDAQ: ELABPmgc Holdings Inc Stock
$1.46-0.01 (-0.68%)
Updated Jun 15, 2026
ELAB Price
$1.46
Fair Value Price
N/A
Market Cap
$6.63M
52 Week Low
$1.34
52 Week High
$309.12
P/E
-0.01x
P/B
0.53x
P/S
2.09x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.27M
Earnings
-$11.11M
Gross Margin
32.7%
Operating Margin
-813.97%
Profit Margin
-873.1%
Debt to Equity
1.07
Operating Cash Flow
-$8M
Beta
1.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ELAB Overview
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ELAB's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ELAB
Ranked#279 of 462
Ranked#279 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.59 | A | |
| $53.00 | A | |
| $16.00 | A |
Be the first to know about important ELAB news, forecast changes, insider trades & much more!
ELAB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ELAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELAB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ELAB is good value based on its book value relative to its share price (0.53x), compared to the US Biotechnology industry average (4.89x)
P/B vs Industry Valuation
ELAB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ELAB due diligence checks available for Premium users.
Valuation
ELAB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.01x
Industry
16.41x
Market
14.3x
ELAB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.53x
Industry
4.89x
ELAB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ELAB's financial health
Profit margin
Revenue
$682.0k
Net Income
-$5.0M
Profit Margin
-728.3%
ELAB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ELAB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$26.0M
Liabilities
$13.4M
Debt to equity
1.07
ELAB's short-term assets ($16.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELAB's short-term assets ($16.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.0M
Investing
-$2.5M
Financing
$14.4M
ELAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ELAB vs Biotech Stocks
Pmgc Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.